Msalam M Sara, MD
Pulmonary Disease · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 35
- 10 carriers
- Offices
- 7
Offices
7 locations · University Healthcare Alliance · Msalam M Sara MD Inc · County of Santa Clara
Hospitals listed: Good Samaritan Hospital · Santa Clara Valley Medical Center · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
35 plans · 10 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sara’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
35 of 35 plans
| Advantage Care (HMO) | Align Senior Care | Listed | Oct 1, 2026 |
| Premier Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Senior Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A72788 · Current
Licensed to practise in California · since 2000 · expires 2028-01-31 · University of Damascus Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$179,723
Medicare paid this office $179,723 for 592 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 243 | $94,187 | $185 |
| Long return visit (40+ min) | 181 | $37,537 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 96 | $20,308 | $106 |
| Return visit (30+ min) | 61 | $9,623 | $84 |
| New patient visit (60+ min) | 60 | $8,963 | $149 |
See all 6 services
| Critical care, first 30-74 minutes | 243 | $94,187 | $185 |
| Long return visit (40+ min) | 181 | $37,537 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 96 | $20,308 | $106 |
| Return visit (30+ min) | 61 | $9,623 | $84 |
| New patient visit (60+ min) | 60 | $8,963 | $149 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $2,841 | $71 |
Who their Medicare patients are
592 Original Medicare patients in 2024. Average age 77 · Under 65 6% · 85 and older 23% · Women 52% · Also on Medicaid 27% · Health risk score 2.32. Above the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Coronary heart disease 55% · Heart failure 48% · Diabetes 46% · COPD 44% · Atrial fibrillation 42% · Chronic kidney disease 39% · Depression 27% · Dementia 26% · Stroke 26% · Cancer 24%.
The office billed $1,118,426, Medicare allowed $232,170 and paid $179,723; for 1,292 services of 26 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 592 | 1,292 | 77 | 2.32 | $1,118,426 | $179,723 |
| 2023 | 558 | 1,351 | 77 | 2.00 | $813,579 | $172,118 |
| 2022 | 509 | 1,356 | 76 | 1.93 | $615,577 | $152,239 |
| 2021 | 437 | 1,476 | 77 | 2.39 | $626,320 | $160,753 |
| 2020 | 507 | 1,362 | 77 | 2.49 | $633,503 | $149,138 |
| 2019 | 303 | 839 | 76 | 2.14 | $404,202 | $100,471 |
| 2018 | 414 | 1,387 | 77 | 2.39 | $784,410 | $193,251 |
| 2017 | 525 | 1,619 | 78 | 2.30 | $817,040 | $241,092 |
| 2016 | 521 | 2,220 | 77 | 2.29 | $705,747 | $291,073 |
| 2015 | 309 | 1,242 | 76 | 2.18 | $437,553 | $184,089 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Critical care, first 30-74 minutes | 223 | $77,493 | $186 |
| Return visit (30+ min) | 226 | $34,487 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 97 | $22,047 | $111 |
| Long return visit (40+ min) | 126 | $19,878 | $129 |
| New patient visit (60+ min) | 71 | $10,827 | $152 |
| Return visit (30+ min) | 17 | $1,500 | $88 |
2022: 10 services
| Critical care, first 30-74 minutes | 166 | $63,972 | $192 |
| Return visit (30+ min) | 229 | $44,216 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 93 | $16,114 | $98 |
| New patient visit (60+ min) | 66 | $10,974 | $166 |
| Long return visit (40+ min) | 41 | $6,149 | $134 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,894 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $2,392 | $70 |
| Test to determine lung volumes using sensors | 39 | $428 | $11 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 36 | $338 | $9 |
| Test to examine how well the lungs exchange gases | 39 | $317 | $8 |
2021: 13 services
| Critical care, first 30-74 minutes | 168 | $73,966 | $198 |
| Return visit (30+ min) | 192 | $45,628 | $89 |
| New patient visit (60+ min) | 60 | $9,882 | $165 |
| Long return visit (40+ min) | 52 | $7,709 | $135 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 62 | $6,782 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $4,263 | $99 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,232 | $180 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $1,196 | $109 |
| Test to determine lung volumes using sensors | 75 | $837 | $11 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $743 | $39 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 76 | $726 | $10 |
| Test to examine how well the lungs exchange gases | 76 | $627 | $8 |
| Short return visit | 12 | $431 | $33 |
2020: 13 services
| Critical care, first 30-74 minutes | 229 | $78,250 | $203 |
| Long return visit (40+ min) | 135 | $24,741 | $95 |
| Return visit (30+ min) | 107 | $11,422 | $74 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 65 | $7,764 | $75 |
| New patient visit (60+ min) | 38 | $6,007 | $158 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,861 | $189 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $3,798 | $95 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 23 | $2,282 | $99 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 37 | $1,899 | $41 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 77 | $939 | $12 |
| Test to determine lung volumes using sensors | 75 | $862 | $11 |
| Test to examine how well the lungs exchange gases | 75 | $636 | $8 |
| Short return visit (20+ min) | 13 | $624 | $48 |
2019: 13 services
| Critical care, first 30-74 minutes | 130 | $55,519 | $198 |
| Long return visit (40+ min) | 91 | $16,015 | $101 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $6,265 | $184 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 38 | $4,546 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 45 | $4,109 | $66 |
| Return visit (30+ min) | 37 | $2,882 | $72 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 20 | $1,824 | $91 |
| Established patient complete exam of visual system | 21 | $1,724 | $75 |
| New patient complete exam of visual system | 11 | $1,027 | $93 |
| Short return visit (20+ min) | 18 | $979 | $47 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 29 | $361 | $12 |
| Test to determine lung volumes using sensors | 27 | $329 | $11 |
| Test to examine how well the lungs exchange gases | 27 | $243 | $8 |
2018: 8 services
| Critical care, first 30-74 minutes | 269 | $119,503 | $195 |
| Return visit (30+ min) | 134 | $45,575 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $8,988 | $94 |
| New patient visit (45+ min) | 37 | $4,968 | $134 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 14 | $1,250 | $89 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 18 | $1,028 | $57 |
| Test to determine lung volumes using sensors | 14 | $799 | $57 |
| Test to examine how well the lungs exchange gases | 14 | $788 | $56 |
2017: 4 services
| Critical care, first 30-74 minutes | 336 | $167,154 | $195 |
| Return visit (30+ min) | 144 | $38,600 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 60 | $15,611 | $93 |
| New patient visit (45+ min) | 69 | $9,814 | $142 |
2016: 14 services
| Critical care, first 30-74 minutes | 325 | $194,980 | $193 |
| Return visit (30+ min) | 125 | $32,109 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 133 | $27,799 | $92 |
| New patient visit (45+ min) | 106 | $15,810 | $149 |
| Short return visit (20+ min) | 42 | $3,780 | $66 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 18 | $2,337 | $106 |
| New patient visit (30+ min) | 19 | $1,913 | $101 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $1,736 | $60 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 19 | $942 | $35 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 64 | $784 | $11 |
| Test to determine lung volumes using gas dilution or washout | 62 | $720 | $11 |
| Test to examine how well the lungs exchange gases | 62 | $532 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 15 | $169 | $11 |
| Test to measure expiratory airflow and volume | 17 | $129 | $8 |
2015: 11 services
| Critical care, first 30-74 minutes | 219 | $139,679 | $193 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 112 | $19,057 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 64 | $6,865 | $65 |
| New patient visit (45+ min) | 28 | $4,272 | $153 |
| Return visit (30+ min) | 27 | $4,259 | $101 |
| New patient visit (30+ min) | 12 | $1,217 | $101 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,168 | $97 |
| Short return visit (20+ min) | 11 | $756 | $69 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 13 | $154 | $12 |
| Test to determine lung volumes using gas dilution or washout | 12 | $133 | $11 |
| Test to examine how well the lungs exchange gases | 12 | $99 | $8 |
Medicaid work
$3,805 in 2024
Medicaid paid $3,805 for 84 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 84 | $3,805 |
| 2024 | 84 | 1 | 15 | $3,805 |
| 2023 | 172 | 1 | 16 | $6,350 |
| 2022 | 23 | 1 | 14 | $730 |
| 2021 | 58 | 1 | 13 | $1,511 |
| 2020 | 41 | 2 | 14 | $1,112 |
| 2019 | 31 | 1 | 12 | $973 |
| 2018 | 72 | 1 | 18 | $14,847 |
See the largest Medicaid services in earlier years
2023
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 172 | $6,350 |
2022
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 23 | $730 |
2021
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 58 | $1,511 |
2020
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 21 | $730 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 20 | $383 |
2019
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 31 | $973 |
2018
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 72 | $14,847 |
Drugs they prescribed that Part D paid
$571,300
Pharmacies billed $571,300 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,353) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
681 generic and 672 brand-name prescriptions · $571,300 in drug cost · 69 antibiotic prescriptions to 43 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ofev | 17 | $224,627 | $13,213 |
| Trelegy Ellipta | 159 | $124,054 | $780 |
| Anoro Ellipta | 133 | $68,297 | $514 |
| Breo Ellipta | 89 | $46,049 | $517 |
| Breztri Aerosphere | 31 | $21,145 | $682 |
See all 34 drugs
| Ofev | 17 | $224,627 | $13,213 |
| Trelegy Ellipta | 159 | $124,054 | $780 |
| Anoro Ellipta | 133 | $68,297 | $514 |
| Breo Ellipta | 89 | $46,049 | $517 |
| Breztri Aerosphere | 31 | $21,145 | $682 |
| Incruse Ellipta | 13 | $9,474 | $729 |
| Combivent Respimat | 12 | $5,640 | $470 |
| Spiriva Handihaler | 11 | $5,581 | $507 |
| Spiriva Respimat | 11 | $5,560 | $505 |
| Tiotropium | 13 | $5,242 | $403 |
| Symbicort | 23 | $5,150 | $224 |
| Budesonide-Formoterol | 31 | $5,024 | $162 |
| Alvesco | 15 | $4,465 | $298 |
| Wixela Inhub | 27 | $4,246 | $157 |
| Advair Hfa | 11 | $3,865 | $351 |
| Sildenafil Citrate | 15 | $3,416 | $228 |
| Breyna | 27 | $3,351 | $124 |
| Albuterol Sulfate Hfa | 140 | $3,271 | $23 |
| Fluticasone-Salmeterol | 13 | $1,295 | $100 |
| Prednisone | 151 | $973 | $6 |
| Potassium Chloride | 12 | $857 | $71 |
| Ventolin Hfa | 13 | $732 | $56 |
| Montelukast | 65 | $673 | $10 |
| Azelastine | 32 | $580 | $18 |
| Levalbuterol Tartrate Hfa | 13 | $488 | $38 |
| Cefdinir | 14 | $477 | $34 |
| Pantoprazole | 32 | $344 | $11 |
| Clarithromycin | 13 | $336 | $26 |
| Fluticasone Propionate | 21 | $300 | $14 |
| Ipratropium | 13 | $300 | $23 |
| Bumetanide | 11 | $245 | $22 |
| Azithromycin | 19 | $129 | $7 |
| Nystatin | 11 | $77 | $7 |
| Gabapentin | 17 | $76 | $4 |
Year by year
| 2024 | 1,353 | 194 | 0% (0) | 50% | $571,300 |
| 2023 | 1,367 | 192 | 0% (0) | 55% | $785,604 |
| 2022 | 1,291 | 191 | None | 56% | $515,506 |
| 2021 | 1,023 | 161 | 0% (0) | 58% | $463,611 |
| 2020 | 610 | 110 | 0% (0) | 57% | $240,526 |
| 2019 | 395 | 71 | 0% (0) | 59% | $178,107 |
| 2018 | 594 | 82 | None | 57% | $170,320 |
| 2017 | 518 | 87 | None | 54% | $156,944 |
| 2016 | 411 | 84 | None | 41% | $82,756 |
| 2015 | 81 | 21 | None | 46% | $10,515 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 31 drugs
| Ofev | 26 | $355,791 | $13,684 |
| Trelegy Ellipta | 179 | $157,303 | $879 |
| Breo Ellipta | 109 | $63,446 | $582 |
| Anoro Ellipta | 100 | $53,016 | $530 |
| Symbicort | 89 | $37,640 | $423 |
| Incruse Ellipta | 26 | $17,109 | $658 |
| Breztri Aerosphere | 20 | $14,338 | $717 |
| Spiriva Handihaler | 19 | $11,142 | $586 |
| Spiriva Respimat | 19 | $10,104 | $532 |
| Xarelto | 14 | $9,661 | $690 |
| Budesonide-Formoterol | 24 | $6,538 | $272 |
| Alvesco | 15 | $5,669 | $378 |
| Wixela Inhub | 34 | $5,254 | $155 |
| Combivent Respimat | 11 | $5,250 | $477 |
| Sildenafil Citrate | 19 | $4,492 | $236 |
| Pulmicort Flexhaler | 15 | $3,514 | $234 |
| Albuterol Sulfate Hfa | 128 | $3,187 | $25 |
| Azelastine | 40 | $1,545 | $39 |
| Ventolin Hfa | 19 | $1,178 | $62 |
| Prednisone | 110 | $1,017 | $9 |
| Ipratropium | 21 | $758 | $36 |
| Pantoprazole | 41 | $714 | $17 |
| Montelukast | 45 | $476 | $11 |
| Cefdinir | 15 | $424 | $28 |
| Clarithromycin | 15 | $391 | $26 |
| Fluticasone Propionate | 30 | $384 | $13 |
| Amoxicillin-Clavulanate Potass | 13 | $294 | $23 |
| Gabapentin | 23 | $243 | $11 |
| Losartan | 16 | $113 | $7 |
| Azithromycin | 15 | $91 | $6 |
| Omeprazole | 12 | $34 | $3 |
2022: 26 drugs
| Trelegy Ellipta | 197 | $149,708 | $760 |
| Anoro Ellipta | 100 | $64,060 | $641 |
| Breo Ellipta | 91 | $54,591 | $600 |
| Symbicort | 90 | $40,161 | $446 |
| Incruse Ellipta | 32 | $18,161 | $568 |
| Advair Diskus | 19 | $11,703 | $616 |
| Breztri Aerosphere | 15 | $8,865 | $591 |
| Xarelto | 11 | $7,190 | $654 |
| Flovent Hfa | 13 | $4,861 | $374 |
| Albuterol Sulfate Hfa | 106 | $4,409 | $42 |
| Dulera | 12 | $3,804 | $317 |
| Pulmicort Flexhaler | 14 | $3,068 | $219 |
| Wixela Inhub | 11 | $2,299 | $209 |
| Ventolin Hfa | 30 | $1,867 | $62 |
| Azelastine | 38 | $1,742 | $46 |
| Prednisone | 122 | $1,309 | $11 |
| Levalbuterol Tartrate Hfa | 13 | $701 | $54 |
| Montelukast | 46 | $671 | $15 |
| Pantoprazole | 29 | $575 | $20 |
| Ipratropium | 15 | $573 | $38 |
| Fluticasone Propionate | 33 | $563 | $17 |
| Nystatin | 17 | $234 | $14 |
| Azithromycin | 25 | $172 | $7 |
| Amoxicillin-Clavulanate Potass | 12 | $146 | $12 |
| Gabapentin | 19 | $134 | $7 |
| Omeprazole | 14 | $73 | $5 |
2021: 26 drugs
| Trelegy Ellipta | 137 | $102,818 | $750 |
| Breo Ellipta | 105 | $47,367 | $451 |
| Anoro Ellipta | 68 | $38,831 | $571 |
| Incruse Ellipta | 34 | $23,309 | $686 |
| Symbicort | 34 | $17,535 | $516 |
| Advair Diskus | 14 | $13,058 | $933 |
| Spiriva Respimat | 14 | $6,950 | $496 |
| Spiriva | 12 | $6,584 | $549 |
| Eliquis | 11 | $5,827 | $530 |
| Budesonide-Formoterol | 18 | $4,899 | $272 |
| Albuterol Sulfate Hfa | 64 | $3,681 | $58 |
| Alvesco | 12 | $3,203 | $267 |
| Wixela Inhub | 11 | $2,988 | $272 |
| Ventolin Hfa | 21 | $1,430 | $68 |
| Montelukast | 50 | $868 | $17 |
| Ipratropium | 22 | $806 | $37 |
| Pantoprazole | 38 | $715 | $19 |
| Prednisone | 76 | $610 | $8 |
| Fluticasone Propionate | 27 | $444 | $16 |
| Famotidine | 22 | $421 | $19 |
| Azelastine | 18 | $399 | $22 |
| Cefdinir | 12 | $325 | $27 |
| Omeprazole | 16 | $245 | $15 |
| Nystatin | 13 | $225 | $17 |
| Losartan | 14 | $107 | $8 |
| Azithromycin | 16 | $95 | $6 |
2020: 16 drugs
| Anoro Ellipta | 87 | $52,313 | $601 |
| Trelegy Ellipta | 60 | $36,850 | $614 |
| Incruse Ellipta | 43 | $20,977 | $488 |
| Breo Ellipta | 41 | $18,335 | $447 |
| Symbicort | 17 | $8,190 | $482 |
| Eliquis | 12 | $6,036 | $503 |
| Albuterol Sulfate Hfa | 28 | $2,071 | $74 |
| Wixela Inhub | 11 | $1,959 | $178 |
| Mometasone Furoate | 20 | $1,629 | $81 |
| Acetazolamide | 11 | $727 | $66 |
| Pantoprazole | 32 | $471 | $15 |
| Cefdinir | 11 | $340 | $31 |
| Montelukast | 33 | $315 | $10 |
| Prednisone | 44 | $290 | $7 |
| Famotidine | 17 | $279 | $16 |
| Azithromycin | 21 | $209 | $10 |
2019: 11 drugs
| Anoro Ellipta | 52 | $31,600 | $608 |
| Breo Ellipta | 32 | $13,798 | $431 |
| Trelegy Ellipta | 23 | $13,101 | $570 |
| Advair Diskus | 14 | $10,274 | $734 |
| Symbicort | 11 | $5,111 | $465 |
| Dymista | 13 | $2,728 | $210 |
| Proair Hfa | 15 | $1,023 | $68 |
| Prednisone | 60 | $340 | $6 |
| Montelukast | 22 | $301 | $14 |
| Famotidine | 14 | $215 | $15 |
| Azithromycin | 13 | $90 | $7 |
2018: 14 drugs
| Anoro Ellipta | 54 | $31,041 | $575 |
| Advair Diskus | 54 | $30,200 | $559 |
| Breo Ellipta | 39 | $21,794 | $559 |
| Symbicort | 28 | $12,029 | $430 |
| Spiriva | 29 | $11,918 | $411 |
| Combivent Respimat | 22 | $9,827 | $447 |
| Incruse Ellipta | 12 | $7,235 | $603 |
| Proair Hfa | 32 | $2,010 | $63 |
| Ventolin Hfa | 28 | $1,903 | $68 |
| Nystatin | 15 | $491 | $33 |
| Levofloxacin | 18 | $344 | $19 |
| Prednisone | 55 | $320 | $6 |
| Montelukast | 25 | $263 | $11 |
| Azithromycin | 12 | $94 | $8 |
2017: 15 drugs
| Advair Diskus | 78 | $37,501 | $481 |
| Spiriva | 31 | $12,787 | $412 |
| Symbicort | 21 | $9,091 | $433 |
| Breo Ellipta | 21 | $8,989 | $428 |
| Combivent Respimat | 20 | $7,333 | $367 |
| Anoro Ellipta | 12 | $5,553 | $463 |
| Proair Hfa | 35 | $2,430 | $69 |
| Ventolin Hfa | 16 | $856 | $54 |
| Levofloxacin | 12 | $380 | $32 |
| Prednisone | 47 | $345 | $7 |
| Valsartan | 14 | $333 | $24 |
| Montelukast | 34 | $325 | $10 |
| Amlodipine Besylate | 19 | $142 | $7 |
| Pantoprazole | 12 | $136 | $11 |
| Famotidine | 13 | $44 | $3 |
2016: 9 drugs
| Advair Diskus | 57 | $27,718 | $486 |
| Combivent Respimat | 31 | $10,771 | $347 |
| Symbicort | 15 | $8,451 | $563 |
| Spiriva | 17 | $5,836 | $343 |
| Proair Hfa | 15 | $887 | $59 |
| Prednisone | 57 | $358 | $6 |
| Levofloxacin | 16 | $250 | $16 |
| Pantoprazole | 11 | $208 | $19 |
| Montelukast | 23 | $191 | $8 |
Money from drug and device companies
$994 in 2025
| 2025 | 10 | 42 | None | $994 |
| 2024 | 7 | 32 | None | $806 |
| 2023 | 6 | 26 | None | $725 |
| 2022 | 10 | 55 | None | $1,196 |
| 2021 | 11 | 73 | None | $1,385 |
| 2020 | 7 | 52 | None | $1,104 |
| 2019 | 10 | 29 | None | $931 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Actelion Pharmaceuticals US | Opsumit | $234 | 6 payments
|
| GlaxoSmithKline | Nucala | $189 | 12 payments
|
| Viatris Specialty | Yupelri | $143 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Airsupra | $134 | 6 payments
|
| Insmed | Arikayce | $103 | 5 payments
|
| Sanofi-Aventis U.S. | Dupixent | $67 | 1 payment
|
See all 42 published payments
| GlaxoSmithKline | Meals · 2025-12-02 | Nucala | $7 |
| Actelion Pharmaceuticals US | Education · 2025-10-17 | Opsumit | $90 |
| GlaxoSmithKline | Meals · 2025-10-17 | Nucala | $10 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-17 | Breztri | $19 |
| Insmed | Education · 2025-10-09 | Brinsupri | $17 |
| Insmed | Meals · 2025-10-09 | Arikayce | $20 |
| Actelion Pharmaceuticals US | Meals · 2025-10-07 | Opsynvi | $29 |
| Sanofi-Aventis U.S. | Education · 2025-09-17 | Dupixent | $67 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-11 | Tezspire | $24 |
| Verona Pharma | Meals · 2025-09-09 | Ohtuvayre | $22 |
| Actelion Pharmaceuticals US | Meals · 2025-09-02 | Opsumit | $28 |
| Insmed | Meals · 2025-08-30 | Arikayce | $25 |
| Insmed | Meals · 2025-08-26 | Arikayce | $20 |
| GlaxoSmithKline | Meals · 2025-08-19 | Nucala | $22 |
| Genzyme | Meals · 2025-08-15 | Dupixent | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-28 | Airsupra | $35 |
| Viatris Specialty | Meals · 2025-07-24 | Yupelri | $20 |
| Actelion Pharmaceuticals US | Meals · 2025-07-16 | Opsumit | $29 |
| GlaxoSmithKline | Meals · 2025-07-07 | Nucala | $20 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-07-01 | Adempas | $20 |
| Viatris Specialty | Meals · 2025-06-23 | Yupelri | $25 |
| Octapharma USA | Meals · 2025-06-19 | Balfaxar | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-17 | Fasenra | $21 |
| Insmed | Meals · 2025-06-02 | Arikayce | $21 |
| Viatris Specialty | Meals · 2025-04-25 | Yupelri | $20 |
| GlaxoSmithKline | Meals · 2025-04-18 | Nucala | $19 |
| GlaxoSmithKline | Meals · 2025-04-16 | Nucala | $4 |
| Actelion Pharmaceuticals US | Meals · 2025-04-08 | Opsumit | $30 |
| GlaxoSmithKline | Meals · 2025-04-02 | Trelegy Ellipta | $22 |
| Verona Pharma | Meals · 2025-04-01 | Ohtuvayre | $17 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-03-25 | Adempas | $20 |
| GlaxoSmithKline | Meals · 2025-03-05 | Nucala | $28 |
| Viatris Specialty | Meals · 2025-02-25 | Yupelri | $34 |
| GlaxoSmithKline | Meals · 2025-02-24 | Nucala | $8 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-15 | Fasenra | $16 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-10 | Airsupra | $20 |
| Viatris Specialty | Meals · 2025-02-10 | Yupelri | $11 |
| GlaxoSmithKline | Meals · 2025-02-04 | Trelegy Ellipta | $31 |
| GlaxoSmithKline | Meals · 2025-01-23 | Trelegy Ellipta | $7 |
| Actelion Pharmaceuticals US | Meals · 2025-01-22 | Opsumit | $28 |
| Viatris Specialty | Meals · 2025-01-11 | Yupelri | $33 |
| GlaxoSmithKline | Meals · 2025-01-10 | Nucala | $10 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $806
| Mylan Specialty L.P. | Yupelri | $209 | 10 payments
|
| AstraZeneca Pharmaceuticals LP | Airsupra | $207 | 9 payments
|
| Actelion Pharmaceuticals US | Opsumit | $184 | 6 payments
|
| Edwards Lifesciences | Hemosphere | $90 | 1 payment
|
| GlaxoSmithKline | Trelegy Ellipta | $84 | 4 payments
|
| Amgen | Tezspire | $16 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Adempas | $15 | 1 payment
|
2023: $725
| AstraZeneca Pharmaceuticals LP | Breztri | $183 | 9 payments
|
| Bayer Healthcare Pharmaceuticals | Adempas | $134 | 2 payments
|
| Mylan Specialty L.P. | Yupelri | $133 | 7 payments
|
| Actelion Pharmaceuticals US | Opsumit | $126 | 3 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $95 | 1 payment
|
| GlaxoSmithKline | Trelegy Ellipta | $53 | 3 payments
|
2022: $1,196
| Actelion Pharmaceuticals US | Uptravi | $390 | 12 payments
|
| AstraZeneca Pharmaceuticals LP | Breztri | $347 | 15 payments
|
| GlaxoSmithKline | Nucala | $168 | 11 payments
|
| Mylan Specialty L.P. | Yupelri | $86 | 3 payments
|
| Genzyme | Dupixent | $76 | 4 payments
|
| Bayer HealthCare Pharmaceuticals | Adempas | $37 | 2 payments
|
| Abbott Laboratories | Confirm Rx | $26 | 2 payments
|
| Novartis Pharmaceuticals | Xolair | $25 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Stiolto Respimat | $24 | 1 payment
|
| Merck Sharp & Dohme | None | $18 | 1 payment
|
2021: $1,385
| GlaxoSmithKline | Nucala | $471 | 29 payments
|
| AstraZeneca Pharmaceuticals LP | Breztri | $277 | 17 payments
|
| Abbott Laboratories | Assurity Pacemaker | $182 | 7 payments
|
| Boehringer Ingelheim Pharmaceuticals | Stiolto Respimat | $151 | 9 payments
|
| Medtronic | Micra | $138 | 3 payments
|
| Actelion Pharmaceuticals US | Opsumit | $50 | 2 payments
|
| Mylan Specialty L.P. | Yupelri | $37 | 2 payments
|
| Advanced Respiratory | Volara System | $30 | 1 payment
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $17 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Adempas | $16 | 1 payment
|
| Genzyme | Dupixent | $15 | 1 payment
|
2020: $1,104
| GlaxoSmithKline | Anoro Ellipta | $493 | 27 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $178 | 7 payments
|
| Medtronic Vascular | Micra | $123 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $108 | 7 payments
|
| Mylan Specialty L.P. | Yupelri | $85 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Adempas | $65 | 4 payments
|
| Actelion Pharmaceuticals US | Opsumit | $50 | 2 payments
|
2019: $931
| Actelion Pharmaceuticals US | Opsumit | $294 | 8 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $169 | 3 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $128 | 5 payments
|
| Medtronic Vascular | Azure | $115 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $63 | 3 payments
|
| Merck Sharp & Dohme | Zerbaxa | $41 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Adempas | $41 | 2 payments
|
| Mylan Specialty L.P. | Yupelri | $39 | 2 payments
|
| Genentech USA | Esbriet | $21 | 1 payment
|
| Allergan | Teflaro | $20 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 94.9 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1760773931
- Licence
- CA A72788California A72788: Current · expires 2028-01-31
- Group
- University Healthcare Alliance · Msalam M Sara MD Inc · County of Santa Clara
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Federal specialty code 207RC0200X (207RC0200X)
- Mailing address
- Po Box 33142, Los Gatos, CA, 95031
- NPI first listed
- 2011-04-22
- NPI last updated
- 2026-08-24
- NPI record certified
- 2026-08-24
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2550 Samaritan Dr Ste D, San Jose, CA, 95124 · 2585 Samaritan Dr, San Jose, CA, 95124